Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Chiome Bioscience Inc. ( (JP:4583) ) just unveiled an announcement.
Chiome Bioscience Inc. reported a modest increase in net sales for the fiscal year 2024, reaching 780 million yen, reflecting a 14.4% rise from the previous year. Despite this growth, the company continues to face financial challenges with significant losses in operating and net income, indicating ongoing struggles within its operations. The financial position improved with an increase in total assets and net assets, showcasing a strengthened equity ratio. The company is cautious about its future financial results, particularly in the drug discovery and development sector, and has only provided forecasts for the drug discovery support business.
More about Chiome Bioscience Inc.
Chiome Bioscience Inc. operates in the biotechnology industry, focusing on drug discovery and development. The company is listed on the Tokyo Stock Exchange and offers products and services related to drug discovery support.
YTD Price Performance: -7.06%
Average Trading Volume: 13,176,481
Technical Sentiment Consensus Rating: Sell
Current Market Cap: Yen16.74B
For an in-depth examination of 4583 stock, go to TipRanks’ Stock Analysis page.